Novo Nordisk A/S

Tweet this page
Registration as it was on 09 Apr 2024
How to read and use this data card.
Download this datacard


Lobbying Costs

1,000,000€ - 1,249,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

3.3 Fte (13)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    Novo Nordisk A/S

    EU Transparency Register

    29570313329-11 First registered on 13 Mar 2010

    Goals / Remit

    Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to serious chronic diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat. We employ more than 60,000 people in 80 countries, and market our products in 170 countries. In 2023, we served more than 40 million patients worldwide. In 2023, we served more than 6 million patients in the EU. More than 30,000 of our employees are based in the EU. Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line).The controlling stake in Novo Nordisk is owned by the Novo Nordisk Foundation. This is a non-profit institution, whose formal purpose is to provide a stable basis for its companies’ operations and to make contributions to scientific, humanitarian and social progress.

    Main EU files targeted

    EU pharmaceutical-related policy, as well as broader health, environmental and business-related policy.


    Head Office
    Novo Nordisk A/SNovo Allé, 1
    Bagsværd 2880
    EU Office
    Square de Meeûs 35
    Brussels 1000


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    2 accreditations were / are live (in bold) for the selected state of 28 May 2024

    Name Start date End Date
    Matthew Thomas Vincent CLAY 27 Oct 2023 25 Oct 2024
    Alexander Von Wildenrath LØVGREEN 08 Apr 2024 08 Apr 2026
    Ms Helen Oberg 12 Apr 2023 26 Apr 2024
    Mr Christian JUUL NYHUS 16 Feb 2023 16 Feb 2024
    Mr Alexander VON WILDENRATH LØVGREEN 16 Feb 2023 16 Feb 2024
    Mr Matthew CLAY 07 Jun 2022 07 Jun 2023
    Mr Vincent CLAY 07 Jun 2022 27 Jun 2022
    Jeppe Torp VESTENTOFT 03 Dec 2019 01 Aug 2020
    Ms Victoria Breck 30 Nov 2019 28 Nov 2020
    Ms Ane Sofie Böhm Nielsen 23 Sep 2014 19 Sep 2015
    Mr Troels Anders RYE-ANDERSEN 08 Aug 2014 06 Aug 2015
    Mr Morten Frank Pedersen 19 Sep 2013 18 Sep 2014
    Ms Engelbertha Maria Rouweler 17 Sep 2013 14 Mar 2014
    Mr Neil David Causey 17 Sep 2013 14 Sep 2014
    Mr Troels Anders RYE-ANDERSEN 07 Jun 2013 06 Jun 2014
    Mr Troels Anders RYE-ANDERSEN 16 Jan 2012 08 Feb 2013

    Complementary Information

    A range of Novo Nordisk colleagues contribute their expertise to activities covered by the Register, directly or through trade associations. We have used 10% relevant working time as the threshold for including colleagues in our FTE calculations.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Companies & groups

  • Networking


    Novo Nordisk is member of:

    - EFPIA - European Federation of Pharmaceutical Industries and Associations

    - Danish Chamber of Commerce (Dansk Erhverv)

    - Danish industry (Dansk industri)

    - Science|Business

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    1,000,000€ - 1,249,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    acumen 25,000€ - 49,999€
    trade council, ministry of foreign affairs, denmark 10,000€ - 24,999€
    politico europe 200,000€ - 299,999€
    fipra 50,000€ - 99,999€
    copenhagen economics 50,000€ - 99,999€
    rud pedersen 50,000€ - 99,999€

    Intermediaries for current year

    copenhagen economics
    rud pedersen

    Closed year Costs

    1,000,000€ - 1,249,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)


    Communication activities

    The LinkedIn account of our CEO, Lars Fruergaard Jørgensen, may sometimes include content relevant to activities covered by the Register:

    Novo Nordisk sponsored Politico Brussels Playbook during the week of 20 February 2023

    In November 2023, Politico Europe published sponsored content from EFPIA, authored by Lars Fruergaard Jørgensen in his role as EFPIA President:

    Other activities

    None declared

  • Meetings


    7 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: All information below comes from European Commission web pages.

Download this datacard